Findings demonstrate how two cancer-related genes interact to spur metastasis and potentially enhance immune checkpoint blockade treatment MD Anderson News Release March 21, 2019 Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond […]
In July, Outside magazine ran a profile of a woman named Elizabeth Parrish. “Liz Parrish Wants to Live Forever,” the headline shouted. A few years earlier, in 2015, Parrish had become the first human guinea pig in an experiment intended to reverse aging through gene therapy. She, and the scientists who designed the therapy, were
Do the Caps of Your Chromosomes Hold the Secret to More Years? Read More »
Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, named Imran Alibhai as its CEO, effective immediately. Alibhai most recently served as a senior vice president and managing director of Houston-based DNAtrix Inc., a clinical-stage biopharmaceutical company developing oncolytic viruses for cancer,
Former M.D. Anderson president’s new Houston company names first CEO Read More »
It was an honor to be in Stockholm to see my good friend, Dr. Jim Allison, receive the Nobel Prize for his lifesaving work in immunotherapy. A very exciting moment for all cancer researchers and patients. Thank you Jim for your devotion to saving lives. Making Cancer History! Check out the below videos for an
Nobel Prize Ceremony Read More »
Host, Dr. Robin Smith, chats with Dr. Ron DePinho, professor of medicine and former president of the University of Texas MD Anderson Cancer Center in Houston and an internationally recognized physician for his basic and translational research in cancer, aging, and age-associated degenerative disorders. DePinho launched the Cancer Moonshot Program, played a critical role in
Robin Smith interviews Ron DePinho Read More »
Sid Mukherjee’s, The Emperor of All Maladies, captures well both the scientific complexity and the deep social and emotional toll of cancer. Cancer is portrayed as a genetically and biologically complex disease that can elude early detection, hamper accurate diagnosis, and resist treatment. We all know someone suffering from cancer or lost due to cancer.
Common Cancer Myths & Misconceptions Read More »
Ron DePinho, a current professor and past president of the University of Texas M.D. Anderson Cancer Center, founded a private cancer drug company that recently closed a $9 million funding round. Tvardi Therapeutics Inc. develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule in our cells that, when left
Former M.D. Anderson president: ‘We need the private sector’ Read More »
As longtime supporters of the University of Texas MD Anderson Cancer Center, it gives us a sense of pride and accomplishment to see the great work of our very own Dr. Jim Allison recognized with the 2018 Nobel Prize in Medicine. This is the first such prize awarded to an MD Anderson scientist, and we
Thanks to Jim, immune checkpoint therapy has transformed not only our institution but the entire cancer field, providing a revolutionary new treatment strategy and real hope for countless cancer patients. In addition, Jim’s story stands as one of the best examples of the importance of sustained investment in basic biomedical research. Guest Editorial: Cancer-Letter-10.5.18
Thank you, Jim Allison Read More »
Last year, the FDA issued a landmark approval for the immune therapy drug pembrolizumab (Keytruda) for the treatment of adult and pediatric metastatic tumors whose cells have defects in their DNA repair machinery. This was the first-ever approval of a site-agnostic drug, which targets a tumor based on its genetic profile instead of its anatomic
How precision medicine can help cancer patients Read More »
Sign up for the latest news and updates from Ron DePinho, MD
